PHVS (Pharvaris NV) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV Land And Improvements?

Pharvaris NV's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

Pharvaris NV Land And Improvements Historical Data

The historical data trend for Pharvaris NV's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV Land And Improvements Chart

Pharvaris NV Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Get a 7-Day Free Trial

Pharvaris NV Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

Pharvaris NV Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Pharvaris NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

9EN:Germany

Address

Emmy Noetherweg 2, Leiden, NLD, 2333 BK

Website

https://www.pharvaris.com

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.